Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRC-PIPAC phase II trial of repetitive ePIPAC-OX monotherapy for unresectable isolated colorectal peritoneal metastases
NL-OMON49271Phase 2Active, not recruiting
- Sponsor
- Catharina Ziekenhuis
- Start
- Oct 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in colorectal cancer (CRC), Appendiceal carcinoma and peritoneal carcinomatosis (PC), sponsored by Catharina Ziekenhuis. Primary endpoint: Major toxicity. Started Oct 2017; status: active, not recruiting.
02
Drugs
oxaliplatin
03
Conditions
colorectal cancer (CRC)Appendiceal carcinomaperitoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NL-OMON49271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49271.